)
Jasper Therapeutics (JSPR) investor relations material
Jasper Therapeutics Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Special meeting set for Nov. 13, 2026; seeks Nasdaq approval for conversion of merger and PIPE preferred stock, ratification of Patrick Crutcher’s board appointment, and authority to adjourn if needed.
Kira acquisition closed July 16, 2026; a private placement closed July 20, 2026, raising $132 million through preferred stock convertible into common shares.
Board recommends FOR all four proposals; merger itself and the merger agreement are not being submitted for a stockholder vote.
Voting matters and shareholder proposals
Merger conversion proposal seeks Nasdaq Rule 5635(a) and (b) approval for common shares issuable on conversion of merger preferred stock and exercise of Kira options; PIPE proposal seeks Rule 5635(d) approval for PIPE preferred conversion.
Each proposal requires a majority of shares present or represented by proxy and entitled to vote; abstentions count against, while broker non-votes do not affect the outcomes.
Proposal 3 asks stockholders to ratify Patrick Crutcher’s appointment; Proposal 4 would authorize adjournment to solicit more votes if support for Proposals 1–3 is insufficient.
Directors and officers agreed to vote shares representing ~1% of pre-transaction common stock FOR Proposals 1–3; the Board recommends FOR each proposal.
Board of directors and corporate governance
Patrick Crutcher joined the Board as a Class I director on July 16, 2026, as Kira’s designee; he also joined the Audit, Compensation, and Nominating and Corporate Governance committees.
Crutcher has 15+ years of biotechnology leadership and business development experience; his appointment remains effective if stockholders do not ratify it, though the Board will consider the vote in evaluating continued service.
Crutcher’s non-employee director terms include $40,000 annual cash compensation and a 15,000-share option grant, with 25% vesting after one year and the remainder monthly over 48 months, subject to continued service.
- A 284.0M-share resale shelf amid conversion, dilution and going-concern risks.JSPR
Registration filing - Conversion votes could unlock major dilution while addressing Nasdaq listing risks.JSPR
Proxy filing - Merger creates a well-funded, multi-asset immunology pipeline with major clinical milestones ahead.JSPR
H.C. Wainwright 28th Annual Global Investment Conference - Shareholders will vote on a reverse stock split, share increase, and adjournment to support compliance and growth.JSPR
Proxy filing - Shareholders will vote virtually on a reverse split and share increase to support compliance and growth.JSPR
Proxy filing - Net loss narrowed, but going concern risk persists despite Kira acquisition and $132M financing.JSPR
Q2 2026 - Briquilimab shows high efficacy and durability in urticaria, with pivotal Beacon data expected soon.JSPR
Stifel 2024 Healthcare Conference - Briquilimab shows strong efficacy and safety in mast cell diseases, with pivotal trials ahead.JSPR
Jefferies Global Healthcare Conference 2025 - Misdiagnosis explained BEACON anomalies; briquilimab showed efficacy and safety in asthma.JSPR
Study Result
Next Jasper Therapeutics earnings date
Next Jasper Therapeutics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)